StonvexLoading…
StonvexStonvexStonvexCore line items from AXGN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $225.21M | $187.34M | $159.01M | $138.58M |
Operating Income | $-7.85M | $-3.29M | $-21.46M | $-29.71M |
Net Income | $-15.70M | $-9.96M | $-21.72M | $-28.95M |
EPS (Diluted) | $-0.34 | $-0.23 | $-0.51 | $-0.69 |
Total Assets | $221.69M | $203.73M | $196.83M | $195.39M |
Total Liabilities | $92.84M | $99.82M | $101.16M | $94.39M |
Cash & Equivalents | $35.55M | $27.55M | $31.02M | $15.28M |
Free Cash Flow OCF − CapEx | $-2.93M | $1.43M | $-19.59M | $-36.14M |
Shares Outstanding | 47.20M | 44.15M | 43.12M | 42.45M |